Form 4: Rhythm Pharma CHRO Exercises, Sells Shares

Rhythm Pharmaceuticals' Chief Human Resources Officer, Pamela J. Cramer, exercised stock options and subsequently sold the acquired common stock for a significant gain.

Summary

• Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, Inc. (RYTM), executed a transaction on December 11, 2025.
• Cramer exercised 3,350 stock options at an exercise price of $27.35 per share.
• Immediately following the exercise, Cramer sold 3,350 shares of common stock at a price of $111 per share.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on August 7, 2025.
• After these transactions, Cramer beneficially owns 20,814 shares of common stock and 8,375 stock options.
• The stock options were granted on February 1, 2023, and vest in 16 substantially equal installments upon completion of each three full months of successive service.

Sentiment

Score: 7

Explanation: The transaction reflects a significant gain for the insider, suggesting strong stock performance. While it's an insider sale, it was pre-planned under a 10b5-1 plan, mitigating negative sentiment. The overall implication is positive for the company's stock value.

Positives

• The reporting person realized a significant profit from exercising options at $27.35 and selling shares at $111, indicating a substantial increase in the company's stock value since the options were granted.
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, which demonstrates planned and compliant insider trading.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market, as it reduces the insider's direct equity stake.

Future Outlook

No specific future outlook or guidance provided in this Form 4.

Industry Context

This insider transaction reflects the company's stock performance and the individual's equity management strategy, rather than broader industry trends or competitive positioning.

Related Party Transactions

• Pamela J. Cramer, Chief Human Resources Officer, exercised stock options and sold common stock, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The transaction demonstrates an insider realizing a substantial profit, which could be seen as a positive signal regarding the company's stock performance. However, it also represents a reduction in direct insider ownership.

Next Steps

• Remaining stock options will continue to vest in 16 substantially equal installments upon completion of each three full months of successive service following the February 1, 2023 grant date.

Key Dates

Recommendation

While the insider sale might raise questions, it was conducted under a pre-established 10b5-1 plan, indicating a systematic approach to managing equity rather than a reaction to new negative information. The significant profit realized by the CHRO suggests strong past performance of the stock. Investors should monitor future insider activity and company fundamentals, but this specific transaction alone does not warrant a change from a 'hold' position, assuming current fundamentals are stable.

Keywords

Rhythm Pharmaceuticals, RYTM, Insider Trading, Form 4, Stock Options, Rule 10b5-1, Pamela J. Cramer, Chief Human Resources Officer, Equity Transaction